drugset
drugset / Trial / NCT04916431

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

NCT04916431 ↗

Phase 1 Completed 18 enrolled ModernaTX, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

There are 2 parts to this study: a single ascending dose (single dose of mRNA-6231) part and a multiple ascending dose (repeat doses of mRNA-6231) part. The main goal of this study is to evaluate the safety and tolerability of escalating doses of single and repeat subcutaneous (SC) administration of mRNA-6231. Dose levels of mRNA-6231 are planned to be investigated in a dose-escalation manner.

Timeline

Start
2021-07-28
Primary completion
2022-08-02
Completion
2022-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-6231 Unknown — Subcutaneous

Indications

No indication recorded.